Carolina Saldana

Carolina Saldana

Auto-generated profile, based on publicly available information

Carolina Saldana

AP-HP, Hopital Henri Mondor, Service d'Oncologie, Univ Paris Est Creteil, TRePCa, F-94010 Creteil, France

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
SCStéphane Culine
Stéphane Culine
VHValentin Harter
Valentin Harter
GGGwenaelle Gravis
Gwenaelle Gravis
AFAude Fléchon
Aude Fléchon
CCChristine Chevreau
Christine Chevreau
CPChristian Pfister
Christian Pfister

1 November 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
MCmathilde cancel
mathilde cancel
GFGaelle Fromont
Gaelle Fromont
CBCyriac Blonz
Cyriac Blonz
CCChristine Chevreau
Christine Chevreau
NRNathalie Rioux-Leclercq
Nathalie Rioux-Leclercq
LALaurence Albiges
Laurence Albiges

8 September 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
LMLucie Meynard
Lucie Meynard
DDDerek Dinart
Derek Dinart
BDBlandine Delaunay
Blandine Delaunay
AFAude Fléchon
Aude Fléchon
CSCarolina Saldana
Carolina Saldana
GRGuilhem Roubaud
Guilhem Roubaud

20 May 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ECEmeline Colomba
Emeline Colomba
LALaurence ALBIGES
Laurence ALBIGES
GTGwenael Le Teuff
Gwenael Le Teuff
TETim Eisen
Tim Eisen
GSGrant D Stewart
Grant D Stewart
R(Renal Cross Chanel Group (RCCG)
Renal Cross Chanel Group (RCCG)
4561 Background: Metastatic Chromophobe renal cell carcinoma (mChRCC) is a rare entity with no specific targeted therapy recommended. We aim to assess the outcome of targeted therapy (TT) in a large cohort of mChRCC patients (pts). Methods: RCCG collected data from 27 centers in France, UK and Italy. Patients’ characteristics, treatments, best response and outcomes were collected. Time to treatment failure (TTF) for first-line treatment was calculated from the initiation of first-line treatment (t0) until failure (progression disease, toxicity, death). Overall survival (OS [95%CI]) was calculated from t0 until death. Survival outcomes were described using Kaplan-Meier method with 95% confidence interval. Results: Overall, 91 mChRCC pts were collected. Among these, 63 were treated with TT with a median follow-up of 3 years (range: 0.1-14). Median age at diagnosis was 58 years with a majority of men (62%, n = 39). Most pts had nephrectomy (92%, n = 58). International Metastatic RCC Database Consortium (IMDC...